FDAnews Device Daily Bulletin

MIVT'S PROPRIETARY STENT COATING TECHNOLOGY COMPLETES MAJOR LONG-TERM ANIMAL STUDY WITH EXCELLENT RESULTS

Nov. 16, 2005
A A

MIV Therapeutics, a leading developer of new generation biocompatible coatings and advanced drug delivery systems, recently announced that a pivotal long-term animal study of its novel stent coating technology has been concluded, with results that were unequivocally successful in demonstrating the coating's excellent biocompatibility and safety. The 6-month study, performed by Center for Research in Cardiovascular Interventions of the Methodist Hospital Research Institute, an independent research organization, indicated that MIVT's Hydroxyapatite-based coatings were excellent candidates for advanced drug-eluting stent coatings.
Business Wire